ThermoDox, Celsion’s temperature-sensitive liposomal encapsulation of common cancer drug doxorubicin, allows focused, concentrated delivery of the drug to the tumor target.
The phase I trial, which is being conducted at the National Institutes of Health (NIH) Clinical Center in Bethesda, Maryland, is designed to determine the safe maximum tolerated dose and pharmacokinetic profile of systemically delivered ThermoDox administered in combination with radio frequency ablation (RFA) in the treatment of liver lesions.
The investigational combination technology is designed to utilize an FDA-approved RFA device to ablate (destroy) the center of the tumor and to thermally activate the ThermoDox liposome, to release its encapsulated doxorubicin to kill remaining viable cancer cells throughout the heated area, including the tumor margins.
Dr Augustine Cheung, Celsion’s president and CEO said, “We are very excited to have treated this patient. This is the first step in Celsion’s clinical plan to develop and commercialize ThermoDox as a heat-activated cancer drug for liver cancer treatment.”
Celsion Corporation is a company dedicated to the development and commercialization of treatment systems for cancer and other diseases using focused-heat energy in combination with other therapeutic devices, heat-activated genes and heat-activated drugs.